IRLAB Wins Green Light for Phase Ib Trial of Novel Apathy Drug in Parkinson’s

IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has provided an announcement.

IRLAB Therapeutics has obtained regulatory and ethical approval to initiate a Phase Ib clinical study of its drug candidate IRL757 in Parkinson’s disease patients suffering from apathy, a disabling symptom for which no approved treatments currently exist. The fully MSRD-funded trial will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland and Spain, building on earlier Phase I studies in healthy adults that demonstrated good absorption, systemic exposure and no serious adverse events. IRL757, which has shown positive effects on cognitive function and motivation in preclinical models through its proposed ability to restore disrupted cortical–subcortical nerve signalling, is being advanced under a collaboration with Otsuka group’s McQuade Center and could emerge as the first approved therapy for apathy in Parkinson’s and other neurodegenerative diseases, targeting a large, currently underserved patient population in the US, Europe and other major markets.

The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.

More about IRLAB Therapeutics AB Class A

IRLAB Therapeutics AB is a Sweden-based biopharmaceutical company focused on discovering and developing novel treatments for Parkinson’s disease and other neurological conditions. Its pipeline includes first-in-class drug candidates targeting debilitating non-motor symptoms such as apathy, aiming to address substantial unmet medical needs in major global markets.

Average Trading Volume: 201,115

Technical Sentiment Signal: Sell

Current Market Cap: SEK162.7M

For an in-depth examination of IRLAB.A stock, go to TipRanks’ Overview page.